19th week of 2015 patent applcation highlights part 39 |
Patent application number | Title | Published |
20150125401 | SMALL MAGNETITE THERAPEUTICS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutics to a cell or subject. | 2015-05-07 |
20150125402 | ANTIMICROBIAL AGENTS - Compounds are used in compositions as antimicrobial agents against microbes, such as for example, | 2015-05-07 |
20150125403 | PERSONAL CARE AND COSMETIC COMPOSITIONS COMPRISING RENEWABLY-BASED, BIODEGRADABLE 1,3-PROPANEDIOL - Disclosed herein are methods of reducing irritation associated with personal care and cosmetic compositions comprising 1,3-propanediol, wherein the 1,3-propanediol in said personal care or cosmetic composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic carbon dioxide emissions to the atmosphere. | 2015-05-07 |
20150125404 | Oral Care Compositions With Improved Rheology - A dentifrice composition containing a polyethylene glycol having an average molecular weight of from about 3,000 to about 8,000, glycerin, precipitated silica, and a fluoride source. The polyethylene glycol forms a crystalline structure in the composition and the composition has a water activity from about 0.25 to about 0.46 measured at about 22° C. | 2015-05-07 |
20150125405 | Methods For Improving Taste And Oral Care Compositions With Improved Taste - Provided herein are compositions and methods relating to oral care compositions with improved taste. One such method includes providing an oral care composition comprising a metal salt, a peroxide, an antimicrobial agent, a bad breath reduction agent, a surfactant, or a combination thereof and adding to the oral care composition a TRPV1 activator and/or vanitrope. | 2015-05-07 |
20150125406 | TOPICAL SKIN CARE COMPOSITION - A topical skin care composition disclosed herein comprises a combination of complexion modifying components, and skin conditioning agents in a cosmetically acceptable vehicle and surprisingly helps achieve, restore and/or maintain a desirable enhanced uniform complexion color and moisturized tone on human skin. In a preferred embodiment, the skin care composition further includes skin protective agents to help ameliorate past sun-induced darkening of the skin and help protect the skin against further ravages from environmental ultraviolet radiation, such as sun-induced pigmentation and sun-induced aging. | 2015-05-07 |
20150125407 | Vesicular Formulations, Uses and Methods - The present invention relates to vesicular formulations for use in the topical administration of a biologically active agent, methods of administering a biologically active agent, a combined preparation comprising a vesicular formulation and a kit comprising a vesicular formulation. | 2015-05-07 |
20150125408 | Natural Insecticide Composition - The present invention disclosed herein is directed to a natural insecticide composition. In one embodiment, the composition includes a mixture of essential oils and a cleanser medium such as soap, shampoo, and the like. In another embodiment, the composition includes a mixture of essential oils and a lotion medium. Preferably, the essential oils in the present composition include catnip oil, neem oil, cedarwood oil, rose geranium oil, and lemon eucalyptus oil. The essential oils can externally release a repelling agent to incapacitate or otherwise discourage the pests, such as ticks and mosquitos. The present invention provides a natural eco-friendly insecticide that is safe for use on skin and hair on humans, as well as animals. | 2015-05-07 |
20150125409 | Ultrasonic Sunless Spray Tanning Device And Method - Disclosed are an ultrasonic sunless spray tanning device and method involving components for ejecting a tanning solution mist atomized by ultrasonic vibrations. | 2015-05-07 |
20150125410 | Hyaluronic Acid Production Promoter And Melanin Production Inhibitor - A hyaluronic acid production promoter and a melanin synthesis inhibitor include soybean saponin as an active ingredient. The soybean saponin can be a soybean saponin aglycone, such as soyasapogenol A and/or soyasapogenol B. The hyaluronic acid production promoter and melanin synthesis inhibitor can be administered transdermally or orally. | 2015-05-07 |
20150125411 | COSMETIC COMPOSITION FOR MAKING UP THE SKIN - The invention relates to a fluid cosmetic skin makeup composition comprising, in a physiologically acceptable medium: (i) at least one continuous oil phase, (ii) at least one sebum-pump filler and pulverulent dyestuffs, (iii) at least one hydrophobic film-forming polymer, and (iv) at least one lipophilic gelling agent which is preferably particulate, the said particulate gelling agent also possibly being a sebum pump, characterized in that the composition comprises a solids content of greater than or equal to 15% and in particular greater than or equal to 20%. The composition according to the invention is comfortable on application and has improved colour remanence, especially in the presence of sebum and/or sweat. | 2015-05-07 |
20150125412 | USE OF A LYSATE OF A CULTURE OF A BACTERIUM OF THE VITREOSCILLA SP. GENUS FOR PREVENTING AND/OR TREATING HYPERSEBORRHOEIC CONDITIONS OF THE SCALP - The present invention relates to the cosmetic use of a lysate of a bacterium or bacteria belonging to the | 2015-05-07 |
20150125413 | COMPOSITION COMPRISING A SPECIFIC ACRYLIC POLYMER AND A SILICONE COPOLYMER, AND METHOD FOR TREATING KERATIN FIBRES USING SAME - The present invention relates to a non-colouring composition for treating keratin fibres comprising an aqueous dispersion of particles of hybrid hydrophobic acrylic film-forming polymer and a linear block silicone copolymer, and also to a method for treating keratin fibres using such a composition. The composition makes it possible to obtain a coating which is persistent towards shampooing operations, which leaves the treated fibres individualized, with an improved cosmetic feel and a provision of mass and volume. | 2015-05-07 |
20150125414 | SPRAY COMPOSITION FOR COMPANION ANIMAL BODIES - A spray composition for companion animal bodies includes a polyoxyethylene fatty acid ester, a polyoxyethylene alkyl ether, a silicone derivative, pantothenic acid, panthenol, PCA-Na, glutamic acid, a vegetable oil, an oil-soluble plant extract, and a rosemary-derived component. Based on the total amount of the composition, the content of the polyoxyethylene fatty acid ester is 10% by weight, the content of the polyoxyethylene alkyl ether is 10% by weight, the content of the silicone derivative is 52% by weight, the content of the pantothenic acid is 5% by weight, the content of the panthenol is 3.0% by weight, the content of the PCA-Na is 3.0% by weight, the content of the glutamic acid is 3.0% by weight, the content of the vegetable oil is 10% by weight, the content of the oil-soluble plant extract is 3.0% by weight, and the content of the rosemary-derived component is 1.0% by weight. | 2015-05-07 |
20150125415 | N-Methyl-N-Acylglucamine-Containing Composition - The invention relates to a composition which contains at least one anionic surfactant, a betaine surfactant, a mixture of N-methyl-N-acylglucamines, the acyl groups of which correspond to those of natural coconut oil and/or palm kernel oil, a glycerol derivative, a solvent and optionally one or more additives. The invention also relates to a method for producing the composition. The invention further relates to the use of the composition for the treatment or care of skin or hair, for example as a shampoo, face cleaner, liquid cleaner or shower gel. | 2015-05-07 |
20150125416 | METHOD FOR PRODUCTION OF STRUCTURED LIQUID AND STRUCTURED LIQUID - The present invention relates to a method for the production of a structured liquid that can be used as hair conditioner, by using a Controlled Deformation Dynamic Mixer. The present invention also relates to a structured liquid containing fatty compound, cationic surfactant, and water, that has a high viscosity with a low concentration of fatty compound and cationic surfactant. The structured liquid is prepared by first mixing fatty compound, cationic surfactant, and water, and subsequently passing this mixture through the Controlled Deformation Dynamic Mixer. | 2015-05-07 |
20150125417 | MITIGATION OF ODOR IN CLEANING MACHINES AND CLEANING PROCESSES - The invention relates to malodor controlling bacteria and related methods and compositions for the control and prevention of malodor. | 2015-05-07 |
20150125418 | Surgical Finger, Hand and Arm Barrier Coating and Covering, Method and System - A protective coating solution, liquid, gel, or film and a method of using such a material to provide a sterile covering for fingers, hands, arms or other selected skin surface for use as a glove substitute. | 2015-05-07 |
20150125419 | TRAIL SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 2015-05-07 |
20150125420 | LIQUID FORMULATION OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 2015-05-07 |
20150125421 | CYTOKINE-BASED FUSION PROTEINS FOR TREATMENT OF IMMUNE DISORDERS - The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided. | 2015-05-07 |
20150125422 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula (I) | 2015-05-07 |
20150125423 | HUMAN M2E PEPTIDE IMMUNOGENS - The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens. | 2015-05-07 |
20150125424 | BACTERIOPHAGE FOR BIOCONTROL OF SALMONELLA AND IN THE MANUFACTURING OR PROCESSING OF FOODS - The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to | 2015-05-07 |
20150125425 | TREATMENT OF LIVER CANCER - An oncolytic herpes simplex virus is disclosed for use in a method of treating primary liver cancer. | 2015-05-07 |
20150125426 | MEDIUM CHAIN DICARBOXYLIC ACIDS, THEIR DERIVATES AND METABOLIC DISORDERS - A composition comprising medium chain dicarboxylic acids and/or derivatives of medium chain dicarboxylic acids can be used to treat or prevent metabolic disorders. The composition can particularly well be used to treat or prevent hyperglycemia, for example diabetes. | 2015-05-07 |
20150125427 | NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein. | 2015-05-07 |
20150125428 | Multipotent Vascular Stem Cells and Methods of Use Thereof - A substantially enriched mammalian multipotent vascular stem cell (MVSC) population is provided, as well as compositions comprising the population. Methods are provided for the isolation, purification, and culture of the MVSCs. The MVSCs are useful in various applications, which are also provided. | 2015-05-07 |
20150125429 | GENE TARGETING METHODS AND TOOLS - Provided herein is a general method of correcting a gene, for example a gene with many known mutations, such as a gene with mutations in many different exons which could vary from subject to subject (e.g., patient), as well as a set of tools (TALENs and gene targeting vectors) to accomplish such method. | 2015-05-07 |
20150125430 | COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS - Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject. | 2015-05-07 |
20150125431 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes. | 2015-05-07 |
20150125432 | Human Persistent Fetal Vasculature Neural Progenitors for Transplantation in the Inner Retina - The invention provides the human persistent fetal vasculature neural progenitor cells for transplantation or other uses such as drug discovery. For example, a cell-based method of therapy is carried out by providing a purified population of human persistent fetal vasculature neural progenitor cells and transplanting the cells into an ocular tissue of a recipient subject. | 2015-05-07 |
20150125433 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS - A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29, miR-30, miR-129, miR-141, miR-148, miR-182, miR-200, miR-376 and Let-7, thereby increasing the insulin content in the pancreatic beta cell. | 2015-05-07 |
20150125434 | COMBINATIONS OF BIOLOGICAL CONTROL AGENTS AND INSECTICIDES OR FUNGICIDES - Compositions are provided that improve overall plant vigor and yield by combining agriculturally effective amounts of at least one environmentally friendly biological control agent and at least one insect control agent and or fungicide. A composition of the present invention is particularly effective in the presence of plant parasitic nematode and fungal species. Along with a benefit of reducing insect pressure, the inventive composition enhances the root system of a plant and improves the establishment of the biological control agent within the rhizosphere, thereby enhancing the effectiveness thereof. Use of a composition of the present invention leads to an overall reduction in crop losses caused by either plant parasitic nematodes or fungi and this reduction is much greater than would have bean expected from application of either component alone. Methods for utilizing compositions of the present invention are also provided. Further the compositions according to this invention display synergistic insecticidal, nematicidal, acaricidal or fungicidal activity. | 2015-05-07 |
20150125435 | Compositions for Controlling Plant Parasitic Nematodes and Methods for Using Same - Aspects of the invention include compositions for controlling plant parasitic nematodes. Compositions according to certain embodiments include a carbon skeleton energy compound, a chelating agent, macronutrients, micronutrients, an ionophore, exotic micronutrients and a plant parasitic nematode antagonist. Methods for using the compositions of the invention to control plant parasitic nematodes and kits having one or more compositions for controlling plant parasitic nematodes are also described. | 2015-05-07 |
20150125436 | PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION - The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof. | 2015-05-07 |
20150125437 | Glycopegylated Factor IX - Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2015-05-07 |
20150125438 | Anti-Inflammatory Peptides and Composition Comprising the Same - The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases. | 2015-05-07 |
20150125439 | CERAMIDE LEVELS IN THE TREATMENT AND PREVENTION OF INFECTIONS - The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients. | 2015-05-07 |
20150125440 | METHOD FOR IMPROVED FIBRIN SEALING - The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue. | 2015-05-07 |
20150125441 | METHODS OF TREATING DEPRESSION AND PAIN - The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering a pharmaceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or biological activity, increasing calcium permeable AMPA (α amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor (CPAR) level, expression, concentration, or biological activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase AMPA receptor currents by slowing the deactivation of open channels and may be, for instance, 2-pyrrolidinone, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA) or LY451646. The agent may also be a protein, RNA or DNA product. | 2015-05-07 |
20150125442 | METHODS FOR TREATING MUSCLE SPECIFIC RECEPTOR KINASE MYASTHENIA GRAVIS - Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG. | 2015-05-07 |
20150125443 | COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES - The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody. | 2015-05-07 |
20150125444 | Molecules with Reduced Effector Function and Extended Half-Lives, Compositions, and Uses Thereof - Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide. | 2015-05-07 |
20150125445 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women. | 2015-05-07 |
20150125446 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR - The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor. | 2015-05-07 |
20150125447 | PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS - The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML. | 2015-05-07 |
20150125448 | METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY - This invention provides methods for determining or predicting response to HER2-directed therapy in an individual. | 2015-05-07 |
20150125449 | Single-Arm Monovalent Antibody Constructs and Uses Thereof - Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations. Provided herein are methods for creation of monovalent antibody constructs that unexpectedly inhibit tumor cell growth and can be internalized and show greater efficacy compared to a bivalent antibody construct at equimolar saturating concentrations. Provided are monovalent antibody constructs for the treatment of HER2 expressing diseases. | 2015-05-07 |
20150125450 | BISPECIFIC ANTIBODIES THAT NEUTRALIZE BOTH TNF-ALPHA AND IL-6: NOVEL THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE - The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-α antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-α or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein. | 2015-05-07 |
20150125451 | COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY - This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody. | 2015-05-07 |
20150125452 | COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 2015-05-07 |
20150125453 | Monoclonal Antibodies and Methods of Use - This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs. | 2015-05-07 |
20150125454 | ANTI-FGFR2 ANTIBODY - The present invention provides an antibody which binds to a fibroblast growth factor receptor. | 2015-05-07 |
20150125455 | ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF - Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 2015-05-07 |
20150125456 | COLON DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon. | 2015-05-07 |
20150125457 | BONE REPAIR PROMOTER - The present invention provides a bone repair promoter containing as an active ingredient at least one kind of B-type natriuretic peptide receptor agonist. | 2015-05-07 |
20150125458 | Anti-CCL17 Antibodies - The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing. | 2015-05-07 |
20150125459 | APELIN PEPTIDES, ANTIBODIES THERETO, AND METHODS OF USE - The present disclosure concerns the use of biologically active apelin peptides and compositions that are processed from larger precursor proteins and further post-translationally modified to influence cell growth. Particular methods are useful for promoting cell growth, while others are particularly useful for inhibiting cell growth. | 2015-05-07 |
20150125460 | ANTI-BCMA ANTIBODIES - This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases. | 2015-05-07 |
20150125461 | BETA-GLUCAN IMMUNOTHERAPEUTIC METHODS - This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder. | 2015-05-07 |
20150125462 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS - The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. | 2015-05-07 |
20150125463 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING - The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. | 2015-05-07 |
20150125464 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 2015-05-07 |
20150125465 | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS - The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers. | 2015-05-07 |
20150125466 | METHODS RELATED TO CANCER TREATMENT - The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“MMP-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of MMP-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher MMP-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy. The present invention also relates to methods for increasing production of tumor infiltrating leucocytes (“TILs”) in a subject, methods of identifying a subject as a candidate for adoptive T-cell therapy using T-cells that primarily express KCa3.1 channels, and methods of treating a subject having melanoma by administering an MMP-23 inhibitor. | 2015-05-07 |
20150125467 | METHODS FOR THE TREATMENT OF B CELL-MEDIATED INFLAMMATORY DISEASES - Methods for treating diseases associated with CXCL13 expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity. | 2015-05-07 |
20150125468 | IL-6 ANTAGONISTS AND USES THEREOF - IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed. | 2015-05-07 |
20150125469 | DIFFERENT STATES OF CANCER STEM CELLS - Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24−, EpCam−CD49P+(for EMT cancers stem cells), ALDH+ and EPCam+CD49r− (for MET cancers stem cells), and CD44+CD24−ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET). | 2015-05-07 |
20150125470 | NOVEL ANTI-SIGLEC-15 ANTIBODY - Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like. | 2015-05-07 |
20150125471 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND DIAGNOTIC OF ANEMIA OF INFLAMMATION - The present invention relates to a compound which inhibits the binding of activin B to ALK3 receptor or a compound which is an inhibitor of activin B expression or ALK3 receptor expression for use in the treatment of anemia of inflammation. The invention also relates to a method for diagnosis anemia of inflammation in a patient comprising: determining the expression level of Activin B in a sample obtained from said patient; and comparing said expression level to a threshold value. | 2015-05-07 |
20150125472 | ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES - The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same. | 2015-05-07 |
20150125473 | NOVEL PROCESS FOR PREPARATION OF ANTIBODY CONJUGATES AND NOVEL ANTIBODY CONJUGATES - The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond. | 2015-05-07 |
20150125474 | PROTEIN-POLYMER-DRUG CONJUGATES - A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described. | 2015-05-07 |
20150125475 | IMMUNOLOGICALLY USEFUL ARGININE SALTS - The invention is in the field of salt forms of an immunopotentiator compound and their formulation for in vivo use. In particular the invention relates to arginine salts. | 2015-05-07 |
20150125476 | IMMUNOGENIC PEPTIDES AND POLYPEPTIDES FOR PROTECTION AGAINST HIV INFECTION - The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form β-hairpin structure. A further aspect of the present invention is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 15, or at least a contiguous 5 amino acid fragment thereof, capable of folding into an alpha-helical structure. These immunogenic peptides can be inserted into an immunogenic scaffold protein to form an immunogenic polypeptide. The immunogenic peptides or immunogenic polypeptides can be used in an immunogenic vaccine composition and in methods of inducing a neutralizing antibody response, or inducing a protective and non-neutralizing antibody response, or protective antibodies, against HIV-1 gp120 in a subject. Isolated antibodies and methods of detecting are also disclosed. | 2015-05-07 |
20150125477 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2015-05-07 |
20150125478 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2015-05-07 |
20150125479 | ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 2015-05-07 |
20150125480 | METHODS FOR CONSTRUCTING ANTIBIOTIC RESISTANCE FREE VACCINES - The present invention provides | 2015-05-07 |
20150125481 | Immunogenic Composition - The present invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. In a further embodiment, the invention discloses an immunogenic composition comprising at least two different staphylococcal polypeptides, each comprising an IgG binding domain. | 2015-05-07 |
20150125482 | Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes - The invention relates to a recombinant polypeptide construct comprising epitopes from | 2015-05-07 |
20150125483 | FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS, GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR - This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Grl/Ag fusion polypeptides. | 2015-05-07 |
20150125484 | Composition for promoting hair growth - A composition for promoting hair growth is provided with fermented and distilled extracts of fermented and distilled extracts of | 2015-05-07 |
20150125485 | METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 2015-05-07 |
20150125486 | ADJUVANTED FORMULATIONS OF PEDIATRIC ANTIGENS - An immunogenic composition comprising a diphtheria toxoid, a tetanus toxoid, a pertussis toxoid, an aluminium salt adjuvant, and a TLR4 agonist. Preferably, the TLR4 agonist and/or at least one of the toxoids is/are adsorbed to the aluminium salt adjuvant. | 2015-05-07 |
20150125487 | Attenuated Pasteurella Multocida Vaccines & Methods of Making & Use Thereof - The present invention provides attenuated | 2015-05-07 |
20150125488 | METHODS AND COMPOSITIONS INVOLVING IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs. | 2015-05-07 |
20150125489 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES - The present invention relates to a process for obtaining an antigen-loaded dendritic cell showing higher viability and migratory capacity towards lymphatic nodes. The invention also relates to vaccines containing said dendritic cells as well as to the use thereof for the treatment of infectious diseases, especially AIDS. | 2015-05-07 |
20150125490 | COMPOSITIONS AND METHODS FOR LUNG REGENERATION - Described herein are stein cells and related factors for treating degenerative and inflammatory disorders of lung tissue. | 2015-05-07 |
20150125491 | Immunomodulating Cyclic Compounds - The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. | 2015-05-07 |
20150125492 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual. | 2015-05-07 |
20150125493 | METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY - Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug. | 2015-05-07 |
20150125494 | Cyclosporine-Containing Non-Irritative Nanoemulsion Ophthalmic Composition - Provided is an ophthalmic composition containing cyclosporine as an active ingredient and including polyethoxylated castor oil or polyethoxylated hydrogenated castor oil, and a method of preparing the same. Particularly, the ophthalmic composition is prepared as a nanoemulsion having a particle diameter of 100 nm or less simply by mixing and stirring an oil phase and an aqueous phase without using a high speed stirring or shearing machine, so that it is very physiochemically stable and storable for a long time. In addition, the ophthalmic composition causes no irritation to eyes. | 2015-05-07 |
20150125495 | ORALLY DISSOLVING THIN FILMS CONTAINING ALLERGENS AND METHODS OF MAKING AND USE - The present invention provides a thin mucoadhesive sublingual film composition which provides improved allergen delivery and efficacy at a smaller dose while prolonging the contact time between the allergen and oral antigen presenting cells (APCs), and therefore minimizing the risk of systemic side effects. The thin film compositions of the present invention are also easier to standardize, and removes any need for measuring allergen doses at the physician's office, and which allows for a simplified dosing schedule. Methods of making the thin film compositions and methods for their use are also disclosed. | 2015-05-07 |
20150125496 | DOSAGE FORM COMPRISING AN ACTIVE INGREDIENT AND A PLURALITY OF SOLID POROUS MICROCARRIERS - The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity. | 2015-05-07 |
20150125497 | Saposin C-DOPS: A Novel Anti-Tumor Agent - Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor. | 2015-05-07 |
20150125498 | NEW PARTICLE STABILIZED EMULSIONS AND FOAMS - The present invention relates to a particle stabilized emulsion or foam comprising at least two phases and solid particles, wherein said solid particles are starch granules and said starch granules or a portion thereof are situated at the interface between the two phases providing the particle stabilized emulsion or foam. The invention further relates to the use of said particle stabilized emulsion or foam for encapsulation of substances chosen from biopharmaceuticals, proteins, probiotics, living cells, enzymes and antibodies, sensitive food ingredients, vitamins, and lipids in food products, cosmetic products, skin creams, and pharmaceutical formulations. | 2015-05-07 |
20150125499 | LIQUID-RETAINING SHEET AND FACIAL MASK - A liquid-retaining sheet contains a liquid-retaining layer that is able to absorb a liquid component, and the liquid-retaining layer is formed from a nonwoven structural member containing a transparent fiber. In the liquid-retaining sheet, the transparency shown below is adjusted to not more than 0.27. | 2015-05-07 |
20150125500 | SILICONE-BASED COPOLYMER RESIN POWDER, MAKING METHOD, AND COSMETICS - A silicone-based copolymer resin powder is prepared by reacting a siloxane oligomer obtained from ring-opening of (a1) a cyclic organosiloxane in the presence of (a3) an acid catalyst and (a4) an anionic surfactant with (a2) a silane coupling agent having an alkoxy group and a polymerizable double bond to obtain (A) a linear or branched organopolysiloxane containing at least 2 silicon-bonded hydroxyl groups per molecule,
| 2015-05-07 |